N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer

被引：0
|
作者：
Haluska, P.
Reinholz, M. M.
Dueck, A. C.
Linden, H. M.
Lingle, W. L.
Bernath, A. M.
Arbushites, M. C.
Youssoufian, H.
Chen, H. X.
Perez, E. A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Scottsdale, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Geisinger Hlth Syst, Danville, PA USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] ImClone Syst, Branchburg, NJ USA
[7] NCI, Canc Therapy Evaluat Program, Rockville, MD USA
[8] Mayo Clin Florida, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS129
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
    Haluska, Paul
    Bernath, Albert M.
    Ballman, Karla V.
    Dueck, Amylou C.
    Linden, Hannah M.
    Goetz, Matthew P.
    Northfelt, Donald W.
    Hou, Xiaonan
    Tenner, Kathleen S.
    Tienchaiananda, Piyawan
    Flickinger, Lynn M.
    Chen, Beiyun
    Chen, Helen X.
    Lingle, Wilma L.
    Pellegrino, Christine M.
    Sponzo, Robert W.
    Reinholz, Monica Madden
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Geyer, Charles E.
    Forster, John
    Lindquist, Deborah
    Chan, Stephen
    Romieu, C. Gilles
    Pienkowski, Tadeusz
    Jagiello-Gruszfeld, Agnieszka
    Crown, John
    Chan, Arlene
    Kaufman, Bella
    Skarlos, Dimosthenis
    Campone, Mario
    Davidson, Neville
    Berger, Mark
    Oliva, Cristina
    Rubin, Stephen D.
    Stein, Steven
    Cameron, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26): : 2733 - 2743
  • [3] Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
    Haddad, Tufia C.
    He, Jun
    O'Sullivan, Ciara C.
    Chen, Beiyun
    Northfelt, Donald
    Dueck, Amylou C.
    Ballman, Karla V.
    Tenner, Kathleen S.
    Linden, Hannah
    Sparano, Joseph A.
    Hopkins, Judith O.
    De Silva, Chamath
    Perez, Edith A.
    Haluska, Paul
    Goetz, Matthew P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) : 477 - 487
  • [4] Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
    Tufia C. Haddad
    Jun He
    Ciara C. O’Sullivan
    Beiyun Chen
    Donald Northfelt
    Amylou C. Dueck
    Karla V. Ballman
    Kathleen S. Tenner
    Hannah Linden
    Joseph A. Sparano
    Judith O. Hopkins
    Chamath De Silva
    Edith A. Perez
    Paul Haluska
    Matthew P. Goetz
    Breast Cancer Research and Treatment, 2021, 188 : 477 - 487
  • [5] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Lin, Nancy U.
    Eierman, Wolfgang
    Greil, Richard
    Campone, Mario
    Kaufman, Bella
    Steplewski, Klaudia
    Lane, Stephen R.
    Zembryki, Denise
    Rubin, Stephen D.
    Winer, Eric P.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 105 (03) : 613 - 620
  • [6] Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Nancy U. Lin
    Wolfgang Eierman
    Richard Greil
    Mario Campone
    Bella Kaufman
    Klaudia Steplewski
    Stephen R. Lane
    Denise Zembryki
    Stephen D. Rubin
    Eric P. Winer
    Journal of Neuro-Oncology, 2011, 105 : 613 - 620
  • [7] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
  • [9] Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Watanabe, J.
    Hamauchi, S.
    Higashi, Y.
    Onozawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Madden, Rebecca
    Kosari, Sam
    Peterson, Gregory M.
    Bagheri, Nasser
    Thomas, Jackson
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (02) : 72 - 80
12345